The initial public offering (IPO) of Hamps Bio Ltd., launched on December 13, has garnered significant investor attention. Positioned on the BSE SME platform, the fixed-price issue aims to raise ₹6.22 crore, signaling a strategic move to strengthen its FMCG division and bolster brand visibility.
Let’s break down the key aspects of this IPO, its potential impacts, and the opportunities it offers for retail investors.
IPO Overview: Key Details You Should Know
- IPO Dates: Opened on December 13, closing on December 17.
- Price Band: Fixed at ₹51 per share.
- Lot Size: 2,000 shares, with a minimum investment of ₹1,02,000.
- Size: Fresh issue of 12.22 lakh shares, raising ₹6.22 crore.
- Reservation:
- Retail Investors: 5.79 lakh shares.
- Non-Institutional Investors (NIIs): 5.79 lakh shares.
- Qualified Institutional Buyers (QIBs): No allocation.
- Allotment & Listing: Allotment finalization on December 18; shares credited by December 19; listing on December 20.
- Book Running Lead Manager: Marwadi Chandarana Intermediaries Brokers Pvt. Ltd.
- Registrar: Bigshare Services Pvt. Ltd.
- Market Maker: Pure Broking.
Investor Response: Robust Demand in Early Stages
The IPO’s first day saw overwhelming interest:
- Total Subscription: 6.48 times overall.
- Retail Investors: Subscribed 11.76 times, showcasing strong demand.
- NIIs: Subscribed 1.75 times, indicating moderate interest.
- Grey Market Premium (GMP): As of December 13, the GMP stood at ₹21, suggesting a potential listing price of ₹72 per share.
These figures highlight the high confidence among retail investors, often driven by the company’s focus on niche markets and robust financial growth.
Business Overview: Diverse Portfolio with a Focus on Innovation
Hamps Bio operates in two key divisions:
- Pharmaceutical Formulations:
- Products include tablets, syrups, capsules, injectables, oils, gels, and powders.
- Distributed across eight Indian states and union territories.
- FMCG Division (FzyEzy Brand):
- Specializes in freeze-dried products such as fruits, vegetables, herbs, and powders.
- Available in 22 Indian states and four international markets, including platforms like Amazon, Flipkart, and Jio Mart.
Financial Performance: Steady Growth
- Revenue: Grew by 16.4% in FY24, reaching ₹6.5 crore.
- Net Profit: Increased by 39.5% to ₹50.07 lakh in FY24 from ₹35.9 lakh in FY23.
These figures underscore the company’s ability to manage resources effectively and expand its market presence.
Use of Proceeds: Strategic Expansion Plans
The IPO proceeds are earmarked for:
- Purchase of Plant and Machinery: Enhancing production capabilities in the FMCG division.
- Brand Visibility: Strengthening marketing efforts to reach wider audiences.
- General Corporate Expenses: Ensuring smooth operational management.
Opportunities and Risks
Opportunities:
- Market Leadership in Niche Segments:
- Hamps Bio’s specialization in freeze-dried products positions it uniquely in a growing FMCG market.
- The pharmaceutical segment benefits from diverse product offerings.
- Expanding E-Commerce Reach:
- Availability on global platforms like Amazon ensures a steady revenue stream from international markets.
Risks:
- Dependence on SME Platform:
- Being listed on the BSE SME platform may limit liquidity and attract primarily retail investors.
- Competitive Landscape:
- Operating in two highly competitive sectors (FMCG and pharmaceuticals) may pressure margins.
- Lack of QIB Participation:
- The absence of qualified institutional buyers could indicate limited interest from large-scale investors.
Final Thoughts: Is Hamps Bio IPO Worth Investing In?
The Hamps Bio IPO presents a compelling opportunity for retail investors, driven by:
- Strong financial performance.
- Diverse product portfolio catering to growing markets.
- Strategic plans to enhance production and brand visibility.
However, investors should remain cautious about liquidity risks associated with SME platforms and the company’s limited scale compared to larger peers.
Consulting with certified financial advisors is recommended before making investment decisions.
By participating in this IPO, investors have the chance to support a growing company with innovative offerings. With robust demand already visible, Hamps Bio’s journey on the BSE SME platform could mark a new chapter in its growth story.
Also, Read –
- International Gemological Institute IPO: Key Insights and Implications
- Final Day! Supreme Facility Management IPO: Check GMP, Subscription Status And More
- Yash Highvoltage IPO Opens: Key Details Investors Need to Know
- Bondada Engineering’s Remarkable Growth: Cricketer Suryakumar Yadav Joins the Journey